Tag: TRUS biopsy

Fourteen months prior to the time of this writing, the world began locking down due to the emerging SARS-CoV-2 viral pandemic and the potentially deadly COVID illness it causes. We were all confused, and studies repeatedly show that normal screening for cancers such as breast, prostate and colorectal dropped significantly... keep reading

Early in 2021, two separate literature reviews were conducted, and both had similar findings. The first included 7 full text articles from which data was assembled and analyzed. Based on standardized erectile function self-report questionnaires, the authors found that... keep reading

Did your doctor say it’s time for a biopsy, based on your PSA results? Do you shudder at the idea? How do you know you really need to have 12+ randomly placed needles throughout your prostate gland? The answers to these questions can be found in a Swedish paper published online July 9, 2021 by keep reading

The rate of newly diagnosed patients with Gleason 3+3 (Grade Group 1) prostate cancer who choose go on Active Surveillance instead of immediate treatment has increased significantly in the last decade. There’s considerable expert opinion that... keep reading

The FDA-approved PCA3 urine test (Progensa) for detecting a biomarker that is overexpressed in prostate cancer (PCa) was acknowledged by the American Urological Association as far back as 2013 as a useful adjunct – along with other PSA derivatives – for determining if a biopsy or repeat biopsy was needed. keep reading

Fusion guided prostate biopsies are the new darling of urologic diagnostic procedures. For decades, the transrectal ultrasound (TRUS) guided 12-plus needle sampling of the gland was the prostate cancer (PCa) diagnostic gold standard, despite its widely recognized shortcoming: Inaccuracy rates of at least 30% on average Overdetecting insignificant PCa while often missing significant PCa Tends keep reading

Do you get an annual physical or wellness check? Is a PSA blood test part of it? If it isn’t, it might be because your doctor took to heart the 2012 bulletin from the US Preventive Services Task Force panel regarding PSA screening. That year, the USPSTF downgraded PSA screening to a D (not recommended keep reading

Prostate cancer is a complex disease, and understanding the full extent of it is crucial before making treatment decisions. Multiparametric MRI (mpMRI) offers a detailed view of your prostate, helping to identify critical information to guide your treatment plan. keep reading